South Shore Capital Advisors Makes New $549,000 Investment in SPDR S&P Biotech ETF $XBI

South Shore Capital Advisors bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,500 shares of the exchange traded fund’s stock, valued at approximately $549,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of SPDR S&P Biotech ETF by 27.3% in the third quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock worth $1,356,582,000 after buying an additional 2,900,633 shares during the period. Bessemer Group Inc. raised its stake in shares of SPDR S&P Biotech ETF by 9.3% in the third quarter. Bessemer Group Inc. now owns 1,632,988 shares of the exchange traded fund’s stock worth $163,624,000 after buying an additional 138,322 shares during the period. Ameriprise Financial Inc. raised its stake in shares of SPDR S&P Biotech ETF by 40.5% in the third quarter. Ameriprise Financial Inc. now owns 1,226,147 shares of the exchange traded fund’s stock worth $122,906,000 after buying an additional 353,351 shares during the period. Meitav Investment House Ltd. raised its stake in shares of SPDR S&P Biotech ETF by 70.3% in the third quarter. Meitav Investment House Ltd. now owns 682,056 shares of the exchange traded fund’s stock worth $68,156,000 after buying an additional 281,602 shares during the period. Finally, Greenhouse Funds LLLP raised its stake in shares of SPDR S&P Biotech ETF by 16.6% in the third quarter. Greenhouse Funds LLLP now owns 675,975 shares of the exchange traded fund’s stock worth $67,733,000 after buying an additional 96,308 shares during the period.

SPDR S&P Biotech ETF Stock Down 0.1%

NYSEARCA XBI opened at $128.80 on Tuesday. The stock’s 50-day moving average price is $125.01 and its 200-day moving average price is $118.78. SPDR S&P Biotech ETF has a 52 week low of $66.66 and a 52 week high of $132.09. The company has a market capitalization of $7.50 billion, a P/E ratio of 11.47 and a beta of 0.93.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.